Cyxone announces strategic intent to position its drug candidate T20K in MS as a prophylactic agent
Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that preclinical findings support the positioning of its drug candidate T20K as a prophylactic agent for the treatment of multiple sclerosis (MS). This indicates that the substance could be used to mitigate or prevent MS episodes and potentially even delay the disease progression. Early disease intervention, such as this, is currently not targeted by other treatments available.The preclinical studies performed last year revealed further understanding of the drug candidate T20K and findings indicate that the drug could